Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JACQUELINE C BARRIENTOS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1396801031
CMS profile
17900
Location
MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$43,965.74

149 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JACQUELINE C BARRIENTOS

NPI 1396801031 · CMS profile ID 17900

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396801031?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JACQUELINE C BARRIENTOS, NPI 1396801031, CMS profile ID 17900. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396801031?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JACQUELINE C BARRIENTOS, NPI 1396801031, CMS profile ID 17900. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396801031?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JACQUELINE C BARRIENTOS, NPI 1396801031, CMS profile ID 17900, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1396801031?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

149 matching records · $43,965.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 149 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–149 of 149.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
TAIHO ONCOLOGY, INC. $19.4704/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055224765 CMS
Kite Pharma, Inc. $16.2704/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025267291 CMS
Pharmacosmos Therapeutics Inc. $21.9604/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046241693 CMS
Janssen Biotech, Inc. $20.0004/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988163557 CMS
Janssen Biotech, Inc. $2.7704/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988163535 CMS
Genentech USA, Inc. $21.1004/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040383469 CMS
Celgene Corporation $17.9904/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015778629 CMS
PFIZER INC. $17.5604/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049426645 CMS
Merck Sharp & Dohme LLC $1,830.0004/05/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048263029 CMS
SERVIER PHARMACEUTICALS LLC $18.3604/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055088841 CMS
Daiichi Sankyo Inc. $19.4103/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006341789 CMS
Celgene Corporation $16.4503/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015778599 CMS
AbbVie Inc. $18.8903/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996211207 CMS
Amgen Inc. $12.9503/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020591683 CMS
AstraZeneca Pharmaceuticals LP $2,055.0003/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011559393 CMS
AVEO Pharmaceuticals, Inc. $32.2403/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049059935 CMS
Kite Pharma, Inc. $24.0103/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025267289 CMS
AstraZeneca Pharmaceuticals LP $34.2203/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015627539 CMS
Celgene Corporation $26.6202/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015778595 CMS
Myriad Genetic Laboratories, Inc. $14.2302/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059763319 CMS
BeiGene USA, Inc. $24.3502/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051183725 CMS
BeiGene USA, Inc. $11,250.0002/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051183717 CMS
BeiGene USA, Inc. $440.1902/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051183719 CMS
BeiGene USA, Inc. $456.2002/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051183721 CMS
BeiGene USA, Inc. $475.8102/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051183723 CMS
Merck Sharp & Dohme LLC $19.0402/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048617739 CMS
Celgene Corporation $20.2102/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015778591 CMS
GENZYME CORPORATION $22.4502/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050482697 CMS
GlaxoSmithKline, LLC. $27.6902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003309049 CMS
Incyte Corporation $22.4902/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044471871 CMS
Incyte Corporation $15.7002/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044471895 CMS
AstraZeneca Pharmaceuticals LP $125.3502/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016153939 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.5702/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055343921 CMS
Seagen Inc. $19.2702/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995676321 CMS
Daiichi Sankyo Inc. $27.4902/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006387261 CMS
Kite Pharma, Inc. $23.6902/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025267287 CMS
AbbVie Inc. $21.4101/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996211205 CMS
BeiGene USA, Inc. $15.1001/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051183727 CMS
Lilly USA, LLC $4,050.0001/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031597081 CMS
Stemline Therapeutics Inc. $26.5901/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040027603 CMS
Genentech USA, Inc. $26.9401/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040383453 CMS
Pharmacosmos Therapeutics Inc. $20.0801/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046241685 CMS
Lilly USA, LLC $17.8801/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031592337 CMS
Celgene Corporation $15.6201/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015778587 CMS
AstraZeneca Pharmaceuticals LP $2,055.0001/16/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015049543 CMS
Janssen Biotech, Inc. $10.1801/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988163525 CMS
Eisai Inc. $19.3201/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023313309 CMS
Merck Sharp & Dohme LLC $16.9701/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048912133 CMS
ADC Therapeutics America, Inc. $19.6601/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053797217 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,165.72 26
PY2020 $22,082.70 14
PY2021 $21,540.25 11
PY2022 $18,502.37 48
PY2023 $43,965.74 149
PY2024 $8,727.99 142
PY2025 $14,988.10 178

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $465,942.56 71
PY2024 Principal investigator $491,031.58 58
PY2023 Principal investigator $17,932.50 3
PY2022 Principal investigator $41,875.05 22
PY2021 Recipient $1,212.00 1
PY2021 Principal investigator $250,864.22 53
PY2020 Principal investigator $120,311.55 57
PY2019 Recipient $1,050.00 1
PY2019 Principal investigator $312,041.00 71

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $144.00 12/31/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202416795
Principal investigator 1 ABBVIE INC. $500.00 12/31/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202416798
Principal investigator 1 BeOne Medicines USA, Inc. $4,548.00 12/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190329891
Principal investigator 1 BeOne Medicines USA, Inc. $6,458.00 12/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190329893
Principal investigator 1 BeOne Medicines USA, Inc. $750.00 12/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190335844
Principal investigator 1 BeOne Medicines Ltd. $1,659.00 12/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190336072
Principal investigator 1 Janssen Research & Development, LLC $10,144.00 12/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391054
Principal investigator 1 Janssen Research & Development, LLC $3,896.00 11/21/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390907
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $36,388.10 11/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1236000514
Principal investigator 1 Janssen Research & Development, LLC $14,923.00 11/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390865
Principal investigator 1 ABBVIE INC. $4,250.00 10/27/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202416783
Principal investigator 1 Janssen Research & Development, LLC $810.00 10/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390930
Principal investigator 1 Janssen Research & Development, LLC $4,685.00 10/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390936
Principal investigator 1 Janssen Research & Development, LLC $3,896.00 10/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390965
Principal investigator 1 Janssen Research & Development, LLC $546.60 10/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390971
Principal investigator 1 ABBVIE INC. $1,920.00 10/09/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202416780
Principal investigator 1 Janssen Research & Development, LLC $25,063.00 10/06/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390825
Principal investigator 1 BeOne Medicines USA, Inc. $812.50 10/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190329895
Principal investigator 1 BeOne Medicines USA, Inc. $750.00 10/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190335838
Principal investigator 1 BeOne Medicines USA, Inc. $1,800.00 10/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190336081
Principal investigator 1 BeOne Medicines USA, Inc. $743.00 10/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190329889
Principal investigator 1 BeOne Medicines USA, Inc. $5,552.00 10/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190336079
Principal investigator 1 ABBVIE INC. $1,833.75 09/03/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202416765
Principal investigator 1 Janssen Research & Development, LLC $3,184.00 09/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391040
Principal investigator 1 Janssen Research & Development, LLC $5,275.00 09/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391048
Principal investigator 1 Janssen Research & Development, LLC $3,896.00 09/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391074
Principal investigator 1 ABBVIE INC. $3,100.00 08/21/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202416761
Principal investigator 1 Celgene Corporation $51,284.06 08/13/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222305590
Principal investigator 1 Janssen Research & Development, LLC $16,463.00 08/04/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391002
Principal investigator 1 ABBVIE INC. $2,500.00 08/01/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202416754
Principal investigator 1 Janssen Research & Development, LLC $315.00 07/25/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390902
Principal investigator 1 Janssen Research & Development, LLC $991.00 07/25/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391091
Principal investigator 1 Janssen Research & Development, LLC $2,800.00 07/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390877
Principal investigator 1 ABBVIE INC. $3,753.75 07/02/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202416748
Principal investigator 1 Janssen Research & Development, LLC $1,536.60 06/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390896
Principal investigator 1 Janssen Research & Development, LLC $2,093.00 06/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390948
Principal investigator 1 Janssen Research & Development, LLC $4,099.00 06/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390977
Principal investigator 1 Genentech, Inc. $34,600.50 06/10/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211550751
Principal investigator 1 ABBVIE INC. $3,667.50 06/03/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202416744
Principal investigator 1 BeiGene, Ltd. $812.50 05/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323034
Principal investigator 1 BeiGene, Ltd. $3,250.00 05/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323036
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 05/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390960
Principal investigator 1 ABBVIE INC. $1,833.75 05/06/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202416720
Principal investigator 1 ABBVIE INC. $6,725.00 05/05/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies No dispute reported 06/30/2026 1202416717
Principal investigator 1 Janssen Research & Development, LLC $24,875.00 05/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391028
Principal investigator 1 Celgene Corporation $44,139.00 05/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222305654
Principal investigator 1 BeOne Medicines USA, Inc. $1,114.00 04/28/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326118
Principal investigator 1 BeOne Medicines USA, Inc. $858.00 04/28/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326444
Principal investigator 1 Genmab A/S $5,820.00 04/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3) No dispute reported 06/30/2026 1235926004
Principal investigator 1 Genmab A/S $525.00 04/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3) No dispute reported 06/30/2026 1235926008
Principal investigator 1 Janssen Research & Development, LLC $2,070.00 04/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390830
Principal investigator 1 Janssen Research & Development, LLC $3,896.00 04/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390942
Principal investigator 1 Janssen Research & Development, LLC $3,896.00 04/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391008
Principal investigator 1 Janssen Research & Development, LLC $3,896.00 04/07/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391085
Principal investigator 1 ABBVIE INC. $1,833.75 04/03/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202416711
Principal investigator 1 Janssen Research & Development, LLC $10,037.00 03/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390890
Principal investigator 1 Janssen Research & Development, LLC $3,896.00 03/14/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391036
Principal investigator 1 BeiGene USA, Inc. $858.00 03/10/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190324810
Principal investigator 1 Janssen Research & Development, LLC $17,614.00 03/10/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175391014
Principal investigator 1 ABBVIE INC. $7,086.25 03/06/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202416707
Principal investigator 1 Janssen Research & Development, LLC $3,100.00 03/06/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390913
Principal investigator 1 Janssen Research & Development, LLC $531.60 03/06/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390918
Principal investigator 1 Genmab A/S $3,100.00 03/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235926000
Principal investigator 1 BeiGene, Ltd. $2,384.00 02/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190320400
Principal investigator 1 Janssen Research & Development, LLC $969.60 02/10/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390991
Principal investigator 1 ABBVIE INC. $3,505.00 02/05/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202416695
Principal investigator 1 Janssen Research & Development, LLC $14,498.00 02/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390870
Principal investigator 1 BeiGene USA, Inc. $11,695.00 01/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190321236
Principal investigator 1 BeiGene USA, Inc. $3,250.00 01/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190324808
Principal investigator 1 Janssen Research & Development, LLC $2,010.00 01/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175390955
Principal investigator 1 ABBVIE INC. $1,833.75 01/02/2025 Covered Recipient Teaching Hospital
MOUNT SINAI MEDICAL CENTER OF FLORID
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202416692